A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma
Conclusions: PEG-BCT-100 in chemo na ïve post-sorafenib HCC is well tolerated with moderate DCR. ASS-negative confers OS advantage over ASS-positive HCC. ASS-negativity is a potential biomarker for OS in HCC and possibly for other ASS-negative arginine auxotrophic cancers. Trial registration number: NCT01092091. Date of registration: March 23, 2010.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Hepatocellular Carcinoma | Investigational New Drugs | Liver Cancer | Study